Saama’s recent $40M funding from Perceptive Advisors was covered by Endpoints News in an article reviewing Saama’s role in the adoption of artificial intelligence to speed up drug discovery and development.
This article asserts that, “Optimization and efficiency are goals that everyone working in R&D can rally around, and AI promises to be a tool that gets more powerful by the hour. In a recent forward-looking report, IQVIA predicted that the adoption of machine learning and AI will grow significantly over the coming 5 years. AI and ML will have an impact on clinical as well as commercial settings, driving drug management and identifying patients.”